Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this randomized phase II trial is to compare progression-free
survival (PFS) in patients randomized to NGR-hTNF plus an anthracycline versus patients
randomized to an anthracycline alone